Guselkumab shows minor added benefit for specific Crohn's disease patients

https://www.news-medical.net/news/20260327/Guselkumab-shows-minor-added-benefit-for-specific-Crohns-disease-patients.aspx The human monoclonal antibody guselkumab has been approved for certain adults with moderately to severely active ulcerative colitis since April 2025. In a benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined whether guselkumab offers an added benefit to these patients.